Literature DB >> 26062020

Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.

Makiko Yasuda1, Angelika L Erwin1, Lawrence U Liu2, Manisha Balwani1,2, Brenden Chen1, Senkottuvelan Kadirvel1, Lin Gan1, M Isabel Fiel3, Ronald E Gordon3, Chunli Yu1, Sonia Clavero1, Antonios Arvelakis4, Hetanshi Naik1, L David Martin5, John D Phillips6, Karl E Anderson7, Vaithamanithi M Sadagoparamanujam7, Sander S Florman2,4, Robert J Desnick1.   

Abstract

Acute intermittent porphyria (AIP) is an autosomal-dominant hepatic disorder caused by the half-normal activity of hydroxymethylbilane (HMB) synthase. Symptomatic individuals experience life-threatening acute neurovisceral attacks that are precipitated by factors that induce the hepatic expression of 5-aminolevulinic acid synthase 1 (ALAS1), resulting in the marked accumulation of the putative neurotoxic porphyrin precursors 5-aminolevulinic acid (ALA) and porphobilinogen (PBG). Here, we provide the first detailed description of the biochemical and pathologic alterations in the explanted liver of an AIP patient who underwent orthotopic liver transplantation (OLT) due to untreatable and debilitating chronic attacks. After OLT, the recipient's plasma and urinary ALA and PBG rapidly normalized, and her attacks immediately stopped. In the explanted liver, (a) ALAS1 mRNA and activity were elevated approximately ~3- and 5-fold, and ALA and PBG concentrations were increased ~3- and 1,760-fold, respectively; (b) uroporphyrin III concentration was elevated; (c) microsomal heme content was sufficient, and representative cytochrome P450 activities were essentially normal; (d) HMB synthase activity was approximately half-normal (~42%); (e) iron concentration was slightly elevated; and (f) heme oxygenase I mRNA was increased approximately three-fold. Notable pathologic findings included nodular regenerative hyperplasia, previously not reported in AIP livers, and minimal iron deposition, despite the large number of hemin infusions received before OLT. These findings suggest that the neurovisceral symptoms of AIP are not associated with generalized hepatic heme deficiency and support the neurotoxicity of ALA and/or PBG. Additionally, they indicate that substrate inhibition of hepatic HMB synthase activity by PBG is not a pathogenic mechanism in acute attacks.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26062020      PMCID: PMC4607616          DOI: 10.2119/molmed.2015.00099

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  30 in total

1.  Liver iron concentration, stainable iron, and total body storage iron.

Authors:  M Barry
Journal:  Gut       Date:  1974-05       Impact factor: 23.059

2.  Egr-1 regulates the transcriptional repression of mouse δ-aminolevulinic acid synthase 1 by heme.

Authors:  Saki Gotoh; Takayuki Nakamura; Takao Kataoka; Shigeru Taketani
Journal:  Gene       Date:  2010-10-29       Impact factor: 3.688

3.  Liver transplantation from donors with acute intermittent porphyria.

Authors:  Joanna K Dowman; Bridget K Gunson; Simon Bramhall; Mike N Badminton; Philip N Newsome
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

4.  Combined liver and kidney transplantation in acute intermittent porphyria.

Authors:  Staffan Wahlin; Pauline Harper; Eliane Sardh; Christer Andersson; Dan Eh Andersson; Bo-Göran Ericzon
Journal:  Transpl Int       Date:  2009-12-16       Impact factor: 3.782

5.  Case report: incomplete septal cirrhosis with liver cell dysplasia.

Authors:  B Le Bail; P H Bernard; M Hervouet; J Carles; C Balabaud; P Bioulac-Sage
Journal:  J Gastroenterol Hepatol       Date:  1997-04       Impact factor: 4.029

6.  A hydrogen-peroxide digestion system for tissue trace-metal analysis.

Authors:  N W Alcock
Journal:  Biol Trace Elem Res       Date:  1987-08       Impact factor: 3.738

Review 7.  Liver transplantation for porphyria: who, when, and how?

Authors:  Avnish Kumar Seth; Michael N Badminton; Darius Mirza; Scott Russell; Elwyn Elias
Journal:  Liver Transpl       Date:  2007-09       Impact factor: 5.799

8.  Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias.

Authors:  J Ostrowski; E Kostrzewska; T Michalak; B Zawirska; W Medrzejewski; A Gregor
Journal:  Gastroenterology       Date:  1983-11       Impact factor: 22.682

9.  Liver transplantation as a cure for acute intermittent porphyria.

Authors:  Zahir F Soonawalla; Taner Orug; Michael N Badminton; George H Elder; Jonathan M Rhodes; Simon R Bramhall; Elwyn Elias
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

10.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Senkottuvelan Kadirvel; Chunli Yu; John D Phillips; Maria I New; Abigail Liebow; Kevin Fitzgerald; William Querbes; Robert J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

View more
  14 in total

Review 1.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

2.  Systemic inflammation in acute intermittent porphyria: a case-control study.

Authors:  E Storjord; J A Dahl; A Landsem; H Fure; J K Ludviksen; S Goldbeck-Wood; B O Karlsen; K S Berg; T E Mollnes; E W Nielsen; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2016-12-15       Impact factor: 4.330

Review 3.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

Review 4.  Acute hepatic porphyrias: Recommendations for evaluation and long-term management.

Authors:  Manisha Balwani; Bruce Wang; Karl E Anderson; Joseph R Bloomer; D Montgomery Bissell; Herbert L Bonkovsky; John D Phillips; Robert J Desnick
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

Review 5.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 6.  Acute hepatic porphyrias: Current diagnosis & management.

Authors:  Karl E Anderson
Journal:  Mol Genet Metab       Date:  2019-07-05       Impact factor: 4.797

7.  Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.

Authors:  Michael Linenberger; Kleber Y Fertrin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 8.  Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.

Authors:  Mohamed Kazamel; Robert J Desnick; John G Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-07       Impact factor: 5.081

Review 9.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

10.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.

Authors:  Amy Chan; Abigail Liebow; Makiko Yasuda; Lin Gan; Tim Racie; Martin Maier; Satya Kuchimanchi; Don Foster; Stuart Milstein; Klaus Charisse; Alfica Sehgal; Muthiah Manoharan; Rachel Meyers; Kevin Fitzgerald; Amy Simon; Robert J Desnick; William Querbes
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-03       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.